Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This study will be conducted to compare Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Other protocol-defined Inclusion/Exclusion Criteria may apply.
Primary purpose
Allocation
Interventional model
Masking
300 participants in 2 patient groups
Loading...
Central trial contact
Incyte Corporation Call Center (US); Incyte Corporation Call Center (ex-US)
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal